Optic nerve

Good News--MS Drugs Taken While Breastfeeding May Not Affect Child Development

Retrieved on: 
Tuesday, March 5, 2024

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.

Key Points: 
  • MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.
  • For the study, researchers used the German MS and Pregnancy Registry to identify 183 infants born to mothers taking monoclonal antibodies while breastfeeding.
  • The first exposures to the medications through breastfeeding ranged from the day a child was born to the ninth month of life.
  • After comparing infants exposed to the medications to infants not exposed, researchers found no differences in their health or development.

Caregivers Cheer First Patients at New Intermountain Primary Children’s Hospital, Miller Family Campus in Lehi, Utah

Retrieved on: 
Monday, February 12, 2024

The Miller Family Campus’ Infusion Center opened for one day before the grand opening to give them the treatments they needed, closer to home.

Key Points: 
  • The Miller Family Campus’ Infusion Center opened for one day before the grand opening to give them the treatments they needed, closer to home.
  • Everyone at the new campus has been so amazing to work with!”
    The new Miller Family Campus is a full-service children’s hospital providing nearly all the same specialty pediatric services that patients receive at the Salt Lake Campus.
  • The Miller Family Campus is part of Intermountain Health’s Primary Promise to build the nation’s model health system for children.
  • For more information about the new Miller Family Campus in Lehi, visit primarychildrens.org/lehi .

Pursuant Health Unveils FDA-Cleared Retinal Imaging Kiosk - a First in On-Demand Healthcare

Retrieved on: 
Friday, January 12, 2024

ATLANTA, Jan. 12, 2024 /PRNewswire/ -- Pursuant Health announced today a breakthrough in making a critical preventive care service more accessible to the American public. Pursuant Health's newest kiosk model, now equipped with state-of-the-art retinal imaging technology, has received 510(k) clearance from the U.S. Federal Drug Administration (FDA). This kiosk is the first to offer self-service retinal imaging, enabling individuals to capture their own images quickly and effortlessly.

Key Points: 
  • Pursuant Health's newest kiosk model, now equipped with state-of-the-art retinal imaging technology, has received 510(k) clearance from the U.S. Federal Drug Administration (FDA).
  • This kiosk is the first to offer self-service retinal imaging, enabling individuals to capture their own images quickly and effortlessly.
  • Leslie Sommers, CEO of Pursuant Health, emphasizes the kiosk's role in simplifying healthcare: "Our goal is to streamline healthcare for everyone involved.
  • Looking ahead, Pursuant Health aspires to leverage retinal imaging for broader health analysis.

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Delta Dental of Tennessee Launches Annual Holiday Campaign With $75,000 Pledge to Children's Hospitals Across Tennessee

Retrieved on: 
Tuesday, November 21, 2023

Delta Dental of Tennessee (Delta Dental) today launched its annual holiday campaign, pledging a collective $75,000 in donations to the seven children’s hospitals across the state.

Key Points: 
  • Delta Dental of Tennessee (Delta Dental) today launched its annual holiday campaign, pledging a collective $75,000 in donations to the seven children’s hospitals across the state.
  • Delta Dental of Tennessee is the state’s largest independent dental benefits carrier with 1.4 million lives covered.
  • As part of the Delta Dental Plans Association, Delta Dental of Tennessee members have access to the largest dental network in the nation with more than 154,000 providers serving more than 443,000 locations.
  • With the simple mission of ensuring healthy smiles, Delta Dental of Tennessee works hard to help members of the communities it serves.

Prevent Blindness Declares Fourth Annual Thyroid Eye Disease Awareness Week as Nov. 13-19, 2023

Retrieved on: 
Thursday, November 9, 2023

CHICAGO, Nov. 9, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has declared Nov. 13-19, 2023, as its fourth annual "Thyroid Eye Disease Awareness (TED) Week." TED, also known as Graves' Eye Disease, is an autoimmune disease in which the immune system causes inflammation and swelling and stimulates the production of muscle tissue and fat behind the eye.

Key Points: 
  • Prevent Blindness provides free educational materials on Thyroid Eye Disease, including new Focus on Eye Health Export series episode, and debuts online art gallery from participants in the Prevent Blindness Art Therapy program
    CHICAGO, Nov. 9, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has declared Nov. 13-19, 2023, as its fourth annual "Thyroid Eye Disease Awareness (TED) Week."
  • TED, also known as Graves' Eye Disease, is an autoimmune disease in which the immune system causes inflammation and swelling and stimulates the production of muscle tissue and fat behind the eye.
  • Because many individuals with TED are more likely to develop depression and anxiety , during TED Awareness Week, Prevent Blindness will also debut a new episode in the Focus on Eye Health Expert Series , "Thyroid Eye Disease and Mental Wellness."
  • "Now in our 4th consecutive year, we are proud to continue to educate the public and provide patients and care partners with support for Thyroid Eye Disease," said Jeff Todd, Prevent Blindness president and CEO.

Stuart Therapeutics Announces Exclusive Worldwide License Agreement with Glaukos Corporation

Retrieved on: 
Wednesday, October 18, 2023

STUART, Fla., Oct. 18, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart") today announced that it has entered into a license agreement with Glaukos Corporation ("Glaukos") under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113 drug candidate for neuroprotection in glaucoma.

Key Points: 
  • STUART, Fla., Oct. 18, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart") today announced that it has entered into a license agreement with Glaukos Corporation ("Glaukos") under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113 drug candidate for neuroprotection in glaucoma.
  • Under the agreement, Stuart will receive an upfront payment, and is eligible for additional development and sales related milestone payments, plus royalties.
  • They bring critical focus on novel therapies, capabilities in drug product design and delivery, and commercial strength worldwide.
  • Stuart Therapeutics is proud to work with Glaukos on this important program," said Eric Schlumpf, President and Chief Executive Officer of Stuart.